MedTrace Logo

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer

NCT00004861 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-08-10

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or giving drugs in different ways may kill more tumor cells.

PURPOSE: Randomized phase II trial to compare the effectiveness of gemcitabine with or without CI-994 in treating patients who have advanced pancreatic cancer.

Conditions

Interventions

DRUG

gemcitabine hydrochloride

DRUG

tacedinaline

Sponsors & Collaborators

Principal Investigators

  • Kathy M. Diener, PharmD · Pfizer Incorporated - Ann Arbor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Completion
2001-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004861 on ClinicalTrials.gov